March 26, 2001
AMERIPATH, INC. ANNOUNCES APPOINTMENT OF BRIAN C. CARR AND E. MARTIN GIBSON TO
BOARD OF DIRECTOR
Riviera Beach, FL, March 26, 2001 - AmeriPath, Inc.
(Nasdaq:PATH), the largest physician and laboratory company
focused on providing anatomic pathology, cancer diagnostic,
genomics, and healthcare information services, today
announced the appointment of two new Directors to its
Board of Directors, replacing Thomas S. Roberts and Timothy
M. Kilpatrick, M.D.
Mr. Brian Carr is the newly appointed President of
AmeriPath. Most recently, he was Chief Executive Officer
and a Director of Inform DX. Mr. Carr was a co-founder,
CEO, and Director of Pathology Consultants of America
(PCA), a predecessor company of Inform DX. Prior to founding
PCA in 1997, Mr. Carr spent two years at PhyCor, most
recently serving as Director, Corporate Services, where
he was responsible for activities related to the acquisition
of multispecialty medical clinics. Previously, Mr. Carr
spent seven years with Allied Clinical Laboratories,
serving in five different positions, most recently as
Vice President, General Manager of the Southwest Division.
Mr. E. Martin Gibson retired from Corning, Incorporated
in 1994 after a 32-year career. His last position at
Corning was Chairman and CEO of Corning Lab Services,
Inc., the company's largest subsidiary. He served as
a Corning Director for 11 years. Mr. Gibson serves as
a Director of International Technology Corporation (NYSE),
an environmental engineering and consulting firm, and
Hardinge, Inc. (NASDAQ), a machine tool company. Mr.
Gibson is a graduate of Yale University and has an MBA
from the University of Pennsylvania.
"We are very pleased to have Mr. Carr and Mr. Gibson
serve on AmeriPath's Board of Directors," said James
C. New, Chairman and Chief Executive Officer. "Both
gentlemen bring fresh perspectives and experience to
the Company."
"Both Mr. Thomas Roberts and Dr. Timothy Kilpatrick
have made tremendous contributions to AmeriPath since
its inception, and have helped build the Company into
what it is today. We wish them both the best of luck
for the future."
AmeriPath, Inc. is the nation's largest company focused
on providing anatomic pathology, cancer diagnostics,
genomics, and physician and laboratory healthcare information
services to physicians, hospitals, national clinical
laboratories and managed care organizations. The Company's
425 physicians provide medical services through 42 outpatient
pathology laboratories, 224 hospital inpatient laboratories,
and 64 outpatient surgery centers in 21 states.
................................................................................................................
The statements contained
in this press release may include "forward-looking
statements" which are based on management's current beliefs
and expectations. Past performance is not necessarily
indicative of future results. In addition, forward-looking
statements - which are identified by words such as "may", "should", "believe", "expect", "anticipate", "estimate" and
similar expressions - as well as any financial and operating
estimates, forecasts and/or projections, are subject
to a number of risks and uncertainties, many of which
involve factors or circumstances which are beyond the
Company's ability to control. These factors, risks and
uncertainties could cause actual results to differ materially
from historical results or those expected, estimated
or anticipated. These include factors, risks and uncertainties
relating to demand for pathology and related services,
pricing, federal and state regulation (and compliance),
reimbursement rates, government and third party payments,
dependence upon pathologists (and need to retain), key
personnel and contracts, completion and integration of
acquisitions and affiliations (and achievement of expected
synergies and/or cost savings), cost and availability
of financing, competitive factors and technology. The
forward looking statements included in this press release
are made as of the date hereof, and the Company undertakes
no obligation to update or revise any such statements,
whether as result of new developments, new information
or otherwise. Further information regarding
risks, uncertainties and other factors that could affect
the Company's financial or operating results, or which
could cause actual results to differ materially from
those expected, estimated or anticipated, are included
in the Company's Form 10-K for the year ended December
31, 1999 and subsequent filings with the SEC.
